3 analysts out of 3 Wall Street brokerage firms rate Niu Technologies (NASDAQ:NIU) as a Buy, while 0 see it as a Sell. The rest 0 describe it as a Hold. NIU stock traded higher to an intra-day high of $8.85. At one point in session, its potential discontinued and the price was down to lows at $7.9. Analysts have set NIU’s consensus price at $14.51, effectively giving it a 75.88% projection on returns. Should the projected estimates be met, then the stock will likely hit its highest price at $17.6 (up 113.33% from current price levels). NIU has a 0% ROE, lower than the 12.53% average for the industry. The average ROE for the sector is 12.98%.
Niu Technologies (NIU) currently trades at $8.25, which is higher by 5.77% its previous price. It has a total of 77.83 million outstanding shares, with an ATR of around 0.47. The company’s stock volume dropped to 0.27 million, worse than 89.15 million that represents its 50-day average. A 5-day increase of about 8.84% in its price means NIU is now 17.86% higher on year-to-date. The shares had marked a $10.20 52-week high price and the 52 week low of $6.04. Overall, it has seen a growth rate of 0 over the last 12 months.
Endologix, Inc. (NASDAQ:ELGX) shares appreciated 3.4% over the last trading period, taking overall 5-day performance up to 20.31%. ELGX’s price now at $6.99 is greater than the 50-day average of $6.52. Getting the trading period increased to 200 days, the stock price was seen at $23.55 on average. The general public currently hold control of a total of 7.22 million shares, which is the number publicly available for trading. The total of shares that it has issued to investors is 10.22 million. The company’s management holds a total of 3%, while institutional investors hold about 70.8% of the remaining shares. ELGX share price finished last trade 21.32% above its 20 day simple moving average and its downbeat gap from 200 day simple moving average is -70.63%, while closing the session with 7.06% distance from 50 day simple moving average.
Endologix, Inc. (ELGX) shares were last observed trading -89.6% down since June 15, 2018 when the peak of $67.2 was hit. Last month’s price growth of 17.07% puts ELGX performance for the year now at -2.37%. Consequently, the shares price is trending higher by 34.53%, a 52-week worst price since Feb. 28, 2019. However, it is losing value with -64.52% in the last 6 months. From a technical perspective, it appears more likely that the stock will experience a Bull Run market as a result of the strong support seen recently between $6.51 and $6.75. The immediate resistance area is now $7.18 Williams’s %R (14) for ELGX moved to 7.25 while the stochastic %K points at 81.44.
ELGX’s beta is 0.49; meaning investors could reap lower returns, although it also poses lower risks. The company allocated $-9.02 per share from its yearly profit to its outstanding shares. Its last reported revenue is $34.69 million, which was -21% versus $44 million in the corresponding quarter last year. The EPS for Dec 19 quarter came in at $-2.2 compared to $-0.8 in the year-ago quarter and had represented 175% year-over-year earnings per share growth. ELGX’s ROA is -21.1%, lower than the 10.46% industry average. Although a more robust percentage would be better, consideration is given to how well peers within the industry performed. Companies within the sector had an ROA of 10.6%.
Estimated quarterly earnings for Endologix, Inc. (NASDAQ:ELGX) are around $-1.57 per share in three months through March with $-1.52 also the estimate for June quarter of the fiscal year. It means the growth is estimated at 1.88% and 15.56%, respectively. Analysts estimate full-year growth to be 13.75%, the target being $-6.21 a share. The upcoming year will see an increase in growth by percentage to 11.27%, more likely to see it hit the $-5.51 per share. The firm’s current profit margin over the past 12 months is -46.3%. ELGX ranks lower in comparison to an average of 13.3% for industry peers; while the average for the sector is 1.56%.